Meclocycline

Drug Profile

Meclocycline

Alternative Names: SNX-1012

Latest Information Update: 20 Jul 2015

Price : $50

At a glance

  • Originator Mucosal Therapeutics LLC
  • Developer Coserics
  • Class Antibacterials; Tetracyclines
  • Mechanism of Action Interleukin 6 inhibitors; NF-kappa B inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Stomatitis

Most Recent Events

  • 01 Aug 2007 SNX 1012 is still in phase II trials for Stomatitis in USA
  • 11 Nov 2005 Phase-II clinical trials in Stomatitis in USA (PO)
  • 22 Jun 2005 Phase I trials have been completed in Stomatitis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top